Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.75 (market cap $29.60B), while Amylx Pharmaceuticals Inc trades at $23.54 (market cap $2.64B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMLX | |
|---|---|---|
Market Cap | $29.60B | $2.64B |
Sector | Health | Health |
52-Week High | $491.22 | $24.19 |
52-Week Low | $205.48 | $7.82 |
Enterprise Value | $27.56B | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
